Skip to main content

Table 1 Patient characteristics at Baseline (n = 64)

From: Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?

Characteristic

Data

Age (y)

74 (53–90)

Time since first diagnosis (y)

8.7 (0.7–26.9)

PSA (ng/ml)

324.56 (0.25–3129.00)

Hb (mg/dl)

11.63 (6.10–15.10)

PLT (103/µl)

228.93 (74–422.00)

WBC (103/µl)

5.77 (2.48–10.78)

Bone involvement (n)

59 (92)

 Uni-/oligometastatic (n)

8 (12)

 Disseminated-/diffuse (n)

51 (80)

TV50 (ml)

107.41 (2.61–877.01)

Previous therapies (n)

 

 Prostatectomy

34 (53)

 Anti-hormonal therapy

62 (97)

 Chemotherapy

35 (55)

 External-beam radiation therapy

53 (83)

 [223Ra]Radiumdichloride

10 (16)